Neuronal NO plays a functional role in many vascular tissues, including MAs (mesenteric arteries). Glucocorticoids alter NO release from endothelium and the CNS (central nervous system), but no results from peripheral innervation have been reported. In the present study we investigated the effects of dexamethasone on EFS (electrical field stimulation)-induced NO release in MAs from WKY (Wistar-Kyoto) rats and SHRs (spontaneously hypertensive rats) and the role of PKC (protein kinase C) in this response. In endothelium-denuded MAs, L-NAME (N G -nitro-Larginine methyl ester) increased the contractile response to EFS only in segments from SHRs. EFS-induced contraction was reduced by 1 μmol/l dexamethasone in segments from SHRs, but not WKY rats, and this effect was abolished in the presence of dexamethasone. EFS induced a tetrodotoxin-resistant NO release in WKY rat MAs, which remained unchanged by 1 μmol/l dexamethasone. In SHR MAs, dexamethasone decreased basal and EFS-induced neuronal NO release, and this decrease was prevented by the glucocorticoid receptor antagonist mifepristone. Dexamethasone did not affect nNOS [neuronal NOS (NO synthase)] expression in either strain. In SHR MAs, incubation with calphostin C (a non-selective PKC inhibitor), Gö6983 (a classic PKC δ and ζ inhibitor), LY379196 (a PKCβ inhibitor) or PKCζ -PI (PKCζ pseudosubstrate inhibitor) decreased both basal and EFS-induced neuronal NO release. Additionally, PKC activity was reduced by dexamethasone. The PKC inhibitor-induced reduction in NO release was unaffected by dexamethasone. In conclusion, results obtained in the present study indicate that PKC activity positively modulates the neuronal NO release in MAs from SHRs. They also reveal that by PKC inhibition, through activation of glucocorticoid receptors, dexamethasone reduces neuronal NO release in these arteries.
INTRODUCTION
Glucocorticoid hormones play an important role in the control of vascular smooth muscle tone by acting on both endothelial and vascular smooth muscle cells through glucocorticoid receptors [1] . In endothelial cells these hormones suppress the production of vasodilatory factors such as prostacyclin or NO and, in smooth muscle cells, they promote an increased response to vasoconstrictor agents, such as catecholamines [1] . However, our previous study has reported that dexamethasone reduced the vasoconstrictor response to noradrenaline and EFS (electrical field stimulation) by decreasing cyclo-oxygenase-2 expression and thromboxane A 2 release in MAs (mesenteric arteries) from SHRs (spontaneously hypertensive rats), [2] . Curiously, this effect was not observed in arteries from normotensive WKY (Wistar-Kyoto) rats, suggesting that the vascular effect of dexamethasone is dependent on mechanisms associated with hypertension [2] . Vascular tone is maintained by an equilibrium among several mechanisms where endothelial, muscular and neuronal cells have an important role. The maintenance of vascular smooth muscle tone is mostly dependent on sympathetic tone. EFS is widely used to study the influence of neurotransmitter release from nerve endings on the vasomotor response. When applied to rat MAs, EFS produces a vasoconstriction that is the integrated result of different newly released neurotransmitters, but mainly noradrenaline from adrenergic nerve terminals. Additionally, different from observations in normotensive WKY rats, neuronal NO also participates in the EFS-induced vasoconstrictor response in MAs from SHRs, acting as a negative modulating factor [3] .
Neuronal NO has been reported to possess a functional role in many vascular tissues, including rat MAs [4, 5] . It is formed by nNOS [neuronal NOS (NO synthase)], and is regulated by different kinases [6] . It has been reported that, by phosphorylating nNOS in the CNS (central nervous system), PKC (protein kinase C) could modulate nNOS activity and thereby increase or decrease NO production [7] [8] [9] . In peripheral vascular innervation from normotensive rats we have demonstrated that classic and atypical PKC isoforms increase neuronal NO release [10] . In addition, in MAs from diabetic [5] and hypertensive [3] rats, this increase in NO release was associated with enhanced PKC activity.
Several studies have reported that glucocorticoid hormones alter NO synthesis/release in both the endothelium [1] and the CNS [11] [12] [13] . Glucocorticoids can both increase [14, 15] and decrease [11, 16] PKC activity in several tissues or cells. Thus, as dexamethasone has a significant effect on the vasoconstrictor response to EFS in MAs from SHRs and neuronal NO plays a role in this response [2] , it is possible that this glucocorticoid hormone may induce changes in the synthesis of this vasodilating factor released by perivascular nitrergic innervation.
Therefore the present study was designed to determine whether dexamethasone modifies basal and/or EFS-induced NO release in MAs from WKY rats and SHRs and also the possible participation of PKC in this dexamethasone-affected NO release.
MATERIALS AND METHODS

Animals and tissue preparation
In the present study, 6-month-old male WKY rats and SHRs were used. Rats were killed by CO 2 inhalation and the superior MA was carefully dissected out, cleaned of connective tissue and placed in KHS (KrebsHenseleit solution; 115 mmol/l NaCl, 2.5 mmol/l CaCl 2 , 4.6 mmol/l KCl, 1.2 mmol/l KH 2 PO 4 , 1.2 mmol/l MgSO 4 ·7H 2 O, 25 mmol/l NaHCO 3 , 11 mmol/l glucose and 0.03 mmol/l Na 2 EDTA) at 4
• C. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85.23, revised in 1996).
Vascular reactivity
The method used for isometric tension recording has been described in detail previously [17] . Briefly, two parallel stainless-steel pins were introduced through the lumen of the vascular segment: one was fixed to the bath wall, and the other connected to a force transducer (Grass FTO3C); this was connected in turn to a model 7D Grass polygraph. For EFS experiments, segments were mounted between two platinum electrodes 0.5 cm apart and connected to a stimulator (Grass model S44) modified to supply the appropriate current strength. Segments were suspended in an organ bath containing 5 ml of KHS at 37
• C continuously gassed with a 95 % O 2 /5 % CO 2 mixture (pH 7.4). Experiments were performed in endothelium-denuded segments to avoid the possible actions by different drugs on endothelial cells that could lead to misinterpretation of results. Endothelium was removed by gently rubbing the luminal surface of the segments with a thin wooden stick. The segments were subjected to a tension of 0.5 g which was readjusted every 15 min during a 90 min equilibration period before drug administration. After this, the vessels were exposed to 75 mmol/l KCl to check their functional integrity. The absence of vascular endothelium was tested by the inability of acetylcholine (10 μmol/l; 2-acetoxyethyltrimethylammonium chloride) to relax segments pre-contracted with noradrenaline [ 
Frequency-response curves to EFS (1, 2, 4, 8 and 16 Hz) and concentration-response curves to the NO donor sodium nitroprusside (10 nmol/l-10 μmol/l) were performed. The parameters used for EFS were 200 mA, 0.3 ms and 1-16 Hz for 30 s with an interval of 1 min between each stimulus, the time required to recover basal tone.
To determine the participation of NO in the EFSinduced response in segments from both groups of rats, l-NAME (N G -nitro-l-arginine methyl ester; 100 μmol/ l), a NOS inhibitor, was added to the bath 30 min before performing the second frequency-response curve.
To analyse the effect of dexamethasone (1 μmol/l; 9α-fluoro-16α-methylprednisolone-21-phosphate disodium salt) on the participation of NO in EFS-induced vasoconstriction, this glucocorticoid was added to the bath 6 h before performing the first frequency-response curve. Afterwards, dexamethasone (1 μmol/l) plus l-NAME (100 μmol/l) were added 30 min before performing the second frequency-response curve.
To analyse the effect of dexamethasone (1 μmol/l) on the vasodilator response induced by NO, concentrationresponse curves to the NO donor sodium nitroprusside were performed in control segments and segments incubated for 6 h with 1 μmol/l dexamethasone.
NO release measurement
MAs from both WKY rats and SHRs were suspended for 4 h in an organ bath containing KHS as indicated for the reactivity experiments. The KHS was replaced with Hepes solution (119 mmol/l NaCl, 1. • C) using a spectrofluorimeter (LS50 PerkinElmer instruments, FL WINLAB Software) with an excitation wavelength set at 495 nm and emission set at 515 nm. The effect of 0.1 μmol/l TTX (tetrodotoxin; a nerve impulse propagation blocker; Sigma-Aldrich), 0.1 μmol/l calphostin C (a non-selective PKC inhibitor), 10 nmol/l Gö6983 (an inhibitor of PKC α, β, γ , δ and ζ isoforms; Calbiochem), 30 nmol/l LY379196 (a PKCβII inhibitor; Eli Lilly and Company) and 1 μmol/l PKCζ -PI (PKCζ pseudosubstrate inhibitor), and 0.1 μmol/l TTX plus either 10 nmol/l Gö6983, 30 nmol/l LY379196 or 1 μmol/l PKCζ -PI on neuronal NO release were studied by incubating the arteries with these drugs 30 min before collecting medium for determination of basal and EFSinduced neuronal NO release. To evaluate the effect of dexamethasone (0.01-1 μmol/l) on neuronal NO release, another set of experiments was performed by adding this drug at the beginning and maintaining it until the end of the experiment. The effects of 0.1 μmol/l TTX alone, 1 nmol/l PDBu (phorbol 12,13-dibutyrate; a PKC activator), 0.1 μmol/l TTX plus 1 nmol/l PDBu, and 0.1 μmol/l calphostin C, 10 nmol/l Gö6983, 30 nmol/l LY379196 or 1 μmol/l PKCζ -PI on neuronal NO release from MAs incubated with dexamethasone for 6 h was studied by incubating these drugs as indicated for control experiments. To analyse the role of glucocorticoid receptors in the effect of dexamethasone, the glucocorticoid receptor antagonist mifepristone (10 μmol/l) was added to the bath 30 min before adding dexamethasone.
EFS-induced NO release was calculated by subtracting the basal NO release from that evoked by EFS. Also, blank measurements were collected in the same way, but from medium without arteries in order to subtract the background emission. The amount of NO released was expressed as arbitrary units/mg of tissue.
Western blot analysis
For nNOS protein expression measurements, superior MAs from WKY rats and SHRs were incubated for 6 h with 1 μmol/l dexamethasone and then homogenized in a boiling buffer comprising 1 mmol/l sodium vanadate, 1 % (w/v) SDS and 0.01 mol/l Tris/HCl (pH 7.4). Homogenates containing 30 μg of protein were electrophoretically separated on SDS/PAGE (7.5 % gel) and transferred on to a PVDF membrane. The membrane was blocked for 2 h at room temperature in a Tris-buffered saline solution [100 mmol/l Tris/HCl (pH 7.4-7.6), 0.9 % (w/v) NaCl, 0.1 % SDS and 0.01 % Tween 20 with 5 % non-fat skimmed milk powder] before being incubated overnight at 4
• C with a mouse monoclonal antibody for nNOS (1:200 dilution; Transduction Laboratories). After washing, the membrane was incubated with a 1:1000 dilution of an anti-mouse IgG antibody conjugated to horseradish peroxidase (Amersham International). The membrane was thoroughly washed, and the inmunocomplexes were detected using an enhanced horseradish peroxidase/luminal chemiluminescence system (ECL plus; Amersham International). The same membrane was used to determine α-actin expression using a monoclonal anti-α-actin antibody (1: 3000 dilution; Sigma-Aldrich).
PKC activity assay
Control and dexamethasone-treated (1 μmol/l) MAs from SHRs were frozen in liquid nitrogen and stored at − 70
• C. PKC activity was determined using a non-radioactive protein kinase assay kit (CalbiochemNovabiochem). The frozen arteries were homogenized in sample preparation buffer containing 50 mmol/l Tris/ HCl (pH 7.4), 10 mmol/l benzamidine, 5 mmol/l EDTA, 10 mmol/l EGTA, 50 mmol/l 2-mercaptoethanol and 1 mmol/l PMSF and centrifuged at 100 000 g for 1 h at 4
• C. Soluble fractions were used to measure protein content with a Coomassie (Bradford) Protein Assay Kit. Then, the supernatant was collected and used for the assay. PKC activity was measured following the manufacturer's protocol. Briefly, samples were added to reaction buffer containing 250 mmol/l Tris/HCl (pH 7.0), 30 mmol/l MgCl 2 , 5 mmol/l EDTA, 10 mmol/l EGTA, 50 mmol/l 2-mercaptoethanol and 1 mmol/l ATP in the positive and negative reaction groups, and 20 mmol/l CaCl 2 and 500 μg/ml phosphatidylserine for the positive reaction group, transferred to a 96-well plate coated with the pseudosubstrate peptide, and then incubated for 20 min at 25
• C. After stopping the reaction and after washing, the plate was incubated for a further 60 min at 25
• C with a biotinylated antibody to phosphorylated pseudosubstrate. After washing, peroxidaseconjugated streptavidin was added to each well and incubated for 60 min at 25
• C. Substrate solution was then added to each well, and after 5 min the reaction was stopped and the plate was read at 492 nm using a microplate reader. Results were expressed as arbitrary units (absorbance/mg of protein).
Data analysis and statistics
The responses elicited by EFS or sodium nitroprusside were expressed as a percentage of the contraction induced by 75 mmol/l KCl or by 1 μmol/l noradrenaline respectively. All results are given as means + − S.E.M. Statistical analysis was performed by comparing the curve obtained in the presence or absence of dexamethasone by means of repeated measured ANOVA followed by a Bonferroni test. In NO release experiments, the statistical analysis was performed using a Student's t test. The number (n) of rats is indicated in the Figure legends. Data analysis was carried out with the GraphPad Prism 3.0 program (GraphPad Software). A P value of less than 0.05 was considered significant.
RESULTS
Vascular reactivity
As previously demonstrated in MAs from WKY rats, the presence of the NO synthesis inhibitor l-NAME did not modify the contractile response to EFS ( Figure 1A ). In contrast, the inhibition of NO synthesis with l-NAME increased the contractile response to EFS in segments from SHRs ( Figure 1B ). In the presence or absence of l-NAME, the EFS-induced contraction was reduced by 1 μmol/l dexamethasone in segments from SHRs, but not WKY rats ( Figure 1C ) and, curiously, the potentiating effect induced by l-NAME on the contractile response to EFS was completely abolished in the presence of this glucocorticoid hormone in segments from SHRs ( Figure 1C) .
In noradrenaline-pre-contracted segments from SHRs, sodium nitroprusside induced a concentration-dependent relaxation in both groups which was not modified by 1 μmol/l dexamethasone (results not shown).
NO release
EFS induced an NO release in MAs from WKY rats which remained unmodified in the presence of 1 μmol/l dexamethasone ( Figure 2A) . Curiously, this EFS-induced NO release was not modified by pre-treatment with TTX ( Figure 2A) .
In MAs from SHRs, pre-incubation with dexamethasone decreased basal and EFS-induced NO release in a dose-dependent manner. In untreated arteries, basal and EFS-induced NO release were decreased by pre-treatment with TTX, whereas in arteries pre-incubated with dexamethasone this release was unchanged ( Figure 2B ).
Calphostin C (0.1 μmol/l) decreased both basal and EFS-induced neuronal NO release in SHR arteries ( Figure 3A) . In the presence of 1 μmol/l dexamethasone, calphostin C did not modify either basal or EFSinduced NO release in these arteries ( Figure 3A) . The effect of dexamethasone on NO release was reversed in the presence of the PKC activator PDBu ( Figure 3A ). In addition, TTX abolished the increase in NO release produced by PDBu in segments incubated with dexamethasone ( Figure 3B ). Pre-incubation with Gö6983, LY379196 or PKCζ -PI decreased basal and EFS-induced NO release ( Figure 4A ). Simultaneous incubation of TTX plus Gö6983, LY379196 or PKCζ -PI decreased basal and EFS-induced neuronal NO to a similar extent in comparison with the effect produced by TTX alone (results not shown). In arteries incubated with 1 μmol/l dexamethasone, Gö6983, LY379196 or PKCζ -PI did not modify basal or EFS-induced neuronal NO release ( Figure 4B ). Pre-treatment with mifepristone did not modify basal or EFS-induced NO release in the MAs from SHRs, but it did prevent the effects of 1 μmol/l dexamethasone on NO release ( Figure 5 ).
nNOS expression
The expression of nNOS was higher in MAs from SHRs than in those from WKY rats. In arteries from both strains, incubation with 1 μmol/l dexamethasone did not affect nNOS expression (Figure 6 ).
PKC activity assay
In superior MAs from SHRs, the PKC activity was significantly decreased by 1 μmol/l dexamethasone 
DISCUSSION
In the present study, we investigated the effects of dexamethasone on EFS-induced neuronal NO release in MAs from normotensive (WKY) rats and SHRs. In arteries from SHRs, EFS induced neuronal NO release, whereas in arteries from WKY rats the released NO had a non-neuronal origin. In segments from SHRs, dexamethasone, through a mechanism involving inhibition of PKC activity, decreased EFS-induced NO release in a concentration-dependent manner, and this decrease was reversed in the presence of the glucocorticoid receptor antagonist mifepristone.
The modulating effect of neuronal NO on contractile responses to EFS can be demonstrated in de-endotheliumized arterial segments exposed to a NOS inhibitor, such as l-NAME. As we have reported previously [2, 3] , pre-incubation with l-NAME does not modify the EFS-induced contraction in segments from WKY rats, although it increases it in segments from SHRs, indicating that, in MAs from this strain, NO decreases the vasoconstriction in response to EFS. When arteries from SHRs were exposed to 1 μmol/l dexamethasone, the increase produced by l-NAME in the vasoconstrictor response to EFS was completely abolished. Since the vasodilator response to the NO donor sodium nitroprusside was not modified by dexamethasone, we speculated that this glucocorticoid could decrease the NO release from perivascular nitrergic innervation. This dose of dexamethasone was selected because glucocorticoids formed in the vascular tissue can locally reach a higher concentration than in plasma, playing an autocrine and/or paracrine role within the vascular wall in physiopathological conditions [17a] .
There are several studies showing that glucocorticoids decrease NO synthesis/release from the vascular endothelium and the CNS [1, [11] [12] [13] . The analysis of basal and EFS-induced NO release in MAs from SHRs and WKY rats indicated that it was higher in segments from SHRs than from WKY rats. In agreement with previous reports [18, 19] , we observed that, in segments from WKY rats, the NO released by EFS seems to come from smooth muscle cells, since NO levels were not modified by pre-incubation with TTX. In segments from SHRs, TTX strongly decreased basal and EFS-induced NO release, indicating that in this strain most of the released NO has a neuronal origin. Dexamethasone did not modify basal or EFS-induced NO release in MAs from WKY rats, although the drug did significantly decrease both basal and EFS-induced NO release in a dose-dependent manner in arteries from SHRs. In this strain, TTX was not able to change the NO release in arteries pre-treated with dexamethasone, suggesting that the observed effect of this glucocorticoid is specific for neuronal NO released from perivascular nitrergic innervation. Our present results confirm the above-cited studies [1, [11] [12] [13] showing that dexamethasone decreases NO release in some tissues, but at the level of the peripheral nervous system, this is the first study to demonstrate that dexamethasone decreases NO released from perivascular nitrergic innervation. To test the possibility that the effects of dexamethasone were mediated by glucocorticoid receptor activation, arteries from SHRs were incubated with the glucocorticoid receptor antagonist mifepristone. Mifepristone did not modify basal or EFS-induced NO release, although it did revert the inhibitory effect of dexamethasone on basal and EFS-induced NO release, indicating that the effect of dexamethasone is mediated through the glucocorticoid receptor. To investigate whether the inhibition of NO release produced by dexamethasone in arteries from SHRs involves changes in nNOS protein expression, Western blot analyses were performed to identify this NOS isoform. nNOS expression was higher in MAs from SHRs than from WKY rats, justifying a functional role for NO in hypertension. On the other hand, dexamethasone did not change nNOS protein expression in MAs from either SHRs or WKY rats, discounting the possibility that the effect of dexamethasone was due to a decrease in nNOS expression in arteries from hypertensive rats.
Previous reports from our group have demonstrated that, in rat MAs, NO synthesis might be regulated by some protein kinases, such as PKA (protein kinase A) and PKC [3, 5, 10, 19, 20] . In some pathological conditions, such as diabetes mellitus or arterial hypertension, we have also described the involvement of PKC and PKA on neuronal NO synthesis in rat MAs [3, 5, 19] . The results from the present study demonstrate that PKC increases neuronal NO release since calphostin C, a nonselective PKC inhibitor, decreased both basal and EFSinduced NO release in MAs from SHRs. PKC comprises a family of several isoenzymes with distinct biochemical characteristics, differential tissue expression and cellular location. They are subdivided into three groups: classic PKCs (α, β and γ ), novel PKCs (δ, ε, η, θ and μ) and atypical PKCs (ζ and λ) [21] . With the exception of PKCμ, all of the PKC isoenzymes co-exist in the CNS [22] . In a previous study we have described that classic and atypical PKC increases neuronal NO release in rat MAs [10] .
Although selective inhibitors for all of the different PKC isoenzymes do not yet exist, it has been reported that certain compounds, such as the staurosporinederived indocarbazole Gö6983, exhibit preferential inhibition for classic PKC, PKCδ, and PKCζ isoforms [23] . Incubation with Gö6983 decreased both basal and EFS-induced NO release in MAs from SHRs. This effect was not modified in the presence of TTX, indicating that these isoforms could be implicated in neuronal NO release from hypertensive rats. This result allowed us to use more specific inhibitory compounds for individual PKC isoenzymes. Both LY379196, a macrocyclic bisindolylmalemide that inhibits PKCβ activity [24] , and PKCζ -PI, a selective PKCζ inhibitor, decreased basal, as well as EFS-induced, NO release. The effect of these drugs was not altered in the presence of TTX, indicating that both PKCβII and PKCζ seem to be implicated in MA neuronal NO release in SHRs. Taking into account that both PKC inhibitors abolished neuronal NO release, it is possible that a sequential or synergistic activation of the PKCβII and PKCζ isoforms could be necessary for neuronal NO release to occur in MAs from SHRs.
It has previously been reported that glucocorticoids can modify PKC activity [11, 15] . Therefore, to assess whether the inhibitory effect of dexamethasone on neuronal NO release involves inhibition of PKC activity, MAs from SHRs were simultaneously incubated with dexamethasone and calphostin C. In arteries pre-incubated with dexamethasone, calphostin C did not modify basal or EFS-induced NO release, indicating that PKC inhibition is involved in decreased neuronal NO release induced by dexamethasone in MAs from SHRs. In addition, the PKC activator PDBu reverted the inhibitory effect of dexamethasone on basal and EFS-induced NO release. Corroborating these results, we observed a decrease in PKC activity in MAs treated with dexamethasone. Simultaneous incubation with PDBu plus TTX abolished the observed effect of PDBu on basal and EFS-induced NO release, indicating that this NO has a neuronal origin. To analyse whether inhibition of PKCβII and/or ζ was implicated in the effects of dexamethasone, MAs from SHRs were incubated with selective inhibitors for these PKC isoforms. We found that neither LY379196 nor PKCζ -PI modified basal or EFS-induced NO release in dexamethasone-treated arteries, in the presence or absence of TTX, suggesting that, by a decrease in PKCβII and PKCζ activities, dexamethasone inhibits NO release by perivascular nitrergic innervation in SHR MAs.
In conclusion, the present study confirms that PKC activity, involving PKCβιι and PKCζ isoforms, enhances the neuronal NO release from perivascular nitrergic innervations of MAs from SHRs. Our results also revealed that, by inhibiting the activation of PKC, dexamethasone reduces neuronal NO release in SHR arteries.
